Key result
Incident colorectal cancer was associated with increased 1-year risks of venous and arterial thromboembolism compared to matched controls.
Why the study?
Patients with colorectal cancer are at increased risk of venous and arterial thromboembolism, but the exact magnitude of risks, predictors, and prognostic consequences remained unclear.
Does incident colorectal cancer increase the risk of venous and arterial thromboembolism compared to matched controls?
Cohort (n=204,714)
Yes
Does incident colorectal cancer increase the risk of venous and arterial thromboembolism compared to matched controls?
Incident colorectal cancer significantly increases the 1-year risk of both venous and arterial thromboembolism, which are associated with increased all-cause mortality.
Answers are grounded in this paper and cite their sources.
Supports thromboembolism vigilance after colorectal cancer diagnosis; extends venous thrombosis data to arterial events but leaves practice change open.
BACKGROUND: Colorectal cancer (CRC) is the third most prevalent cancer type. CRC-patients are at increased risk of venous and arterial thromboembolism (TE), but the magnitude of the risks, their predictors and consequences are not exactly known. OBJECTIVES: We aimed to determine incidence, predictors and prognosis of TE after incident CRC in a large, unselected population. METHODS: Using data from Statistics Netherlands and the Netherlands Comprehensive Cancer Organization, all incident CRC-patients were identified between 2013 and 2018 plus a sample of 1:2 age- and sex-matched control subjects. Incidence rates and cumulative incidences for TE were estimated. Predictor variables for TE were explored by univariable Cox regression. The association between TE and all-cause mortality was evaluated by multivariable time-dependent Cox regression. RESULTS: 68,238 incident CRC-patients were matched to 136,476 controls. CRC-patients had a 1-year cumulative venous TE (VTE) incidence of 1.93 % (95%CI 1.83-2.04), versus 0.24 % (95%CI 0.21-0.27) in controls (HR 8.85; 95%CI 7.83-9.99). For arterial TE (ATE), this was 2.74 % (95%CI 2.62-2.87) in CRC versus 1.88 % (95%CI 1.81-1.95) in controls (HR 1.57; 95%CI 1.47-1.66). Cancer stage, surgery, chemotherapy and asthma were predictors for VTE, whereas age, prior ATE and Parkinson's disease were predictors for ATE. CRC patients with TE had an increased risk of all-cause mortality (VTE HR; 3.68 (95%CI 3.30-4.10, ATE HR; 3.05 (95%CI 2.75-3.39)) compared with CRC-patients without TE. CONCLUSIONS: This Dutch nationwide cohort study adds detailed knowledge on the risk of VTE and ATE, their predictors and prognosis in CRC-patients. These findings may drive TE prophylactic management decisions.
No takes yet. Share an insight, caveat, or question.
Anijs et al. (2023) conducted a cohort in Colorectal cancer (n=204,714). Colorectal cancer vs. Age- and sex-matched controls was evaluated on 1-year cumulative venous thromboembolism (VTE) (HR 8.85, 95% CI 7.83-9.99). Incident colorectal cancer was associated with increased 1-year risks of venous and arterial thromboembolism compared to matched controls.
Synapse has enriched 10 related papers. Consider them for comparative context: